European Market Report for Modern Insulin 2016 - MedCore
|出版商||iData Research Inc.||商品編碼||370781|
|出版日期||內容資訊||英文 89 Pages
|歐洲的新型胰島素市場分析 European Market Report for Modern Insulin 2016 - MedCore|
|出版日期: 2016年09月01日||內容資訊: 英文 89 Pages||
The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern insulin market was the long-acting insulin segment, which represented nearly 50% of the total market value. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin and premixed insulin segments. Combined with modest appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total modern insulin market over the forecast period.
Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics' immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.